Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

129.21 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 328,560
Open 129.21
Bid (Size) 128.50 (25)
Ask (Size) 128.58 (6)
Prev. Close 129.21
Today's Range 129.21 - 129.21
52wk Range 75.56 - 138.28
Shares Outstanding N/A
Dividend Yield 1.37%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Demand Soars For Novo Nordisk's Weight-Loss Drug Wegovy Despite Supply Constraints And Eli Lilly Competition
The Danish pharmaceutical company is now shipping more introductory doses of Wegovy to the U.S., as it grapples with supply constraints and competition from Eli Lilly. 
Via Benzinga
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property

Performance

YTD
+26.54%
+26.54%
1 Month
+1.30%
+1.30%
3 Month
+12.61%
+12.61%
6 Month
+32.28%
+32.28%
1 Year
+54.56%
+54.56%

More News

Read More
Profit from the Panic: 3 Stocks to Pounce on When They Become Steals
Via InvestorPlace
Moody’s, Booking, DraftKings, Amgen Stocks In Focus Ahead Of Earnings
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Analyzing NYSE:NVO's Dividend Potential.
Via Chartmill
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
Via Benzinga
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Consumer Stocks.
Via InvestorPlace
Setback For Novo Nordisk? Denmark Shifts Prescription Guidelines, Favoring Cost-Effective Alternatives For Ozempic
Via Benzinga
How Consumer Demand Is Impacting Taiwan Semiconductor Manufacturing Co.
Via The Motley Fool
3 of Europe’s ‘Magnificent 18’ Stocks That You Can Buy in the U.S.
Via InvestorPlace
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) a Strong Candidate for Quality Investing?
Via Chartmill
Eli Lilly Stock Jumps On Strong Earnings, Guidance As Zepbound Sales Easily Beat
Via Investor's Business Daily
Billionaire Investor Jim Simons Just Bought These 3 "Magnificent Seven" Stocks
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is Viking Therapeutics Incredibly Undervalued?
Via The Motley Fool
Forget Nvidia, These Unstoppable Stocks Are Better Buys
Via The Motley Fool
1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On
Via The Motley Fool
MarketBeat Week in Review – 4/22 - 4/26
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
Via Benzinga
3 Biotech Stocks With Skyrocketing Potential: April 2024
Via InvestorPlace
Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market
Via The Motley Fool
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
Via InvestorPlace
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Via The Motley Fool
Better Buy: Pfizer vs. Viking Therapeutics
Via The Motley Fool
3 Stocks With the Potential to Surpass Analyst Expectations for 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.